Abstract

) The Northwest Community Clinical Oncology Program has been in existence sine 1983, and is now applying for competitive renewal. The Northwest CCOP consists of 42 participating physicians, including medical and radiation oncologists, and 11 hospital facilities located in Southwestern Washington and Norther Oregon. The Northwest CCOP utilizes five research bases, to include the Southwest Oncology Group, M.D. Anderson Cancer Center, University of Rochester Cancer Center, the National Surgical Adjuvant Breast and Bowel Project and the Radiation Therapy Oncology Group. The objective of the Northwest CCOP is to provide community physicians the opportunity of continued participation in a wide variety of clinical trials sponsored by these research bases, to include not only treatment but cancer prevention and control trials. Through this mechanism, the latest and most up-to-date cancer treatment regimens can be provided to patients. It is anticipated that further increase in accrual to clinical trials will be possible throughout the next five years. The funds obtained through a successful application will be used to support the administration of these activities.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035281-19
Application #
6512458
Study Section
Special Emphasis Panel (ZCA1-RLB-7 (J3))
Program Officer
Cornelison, Terri L
Project Start
1983-09-15
Project End
2003-05-31
Budget Start
2002-06-01
Budget End
2003-05-31
Support Year
19
Fiscal Year
2002
Total Cost
$597,793
Indirect Cost

  Institution

Name
Tacoma General Hospital
Department
Type
DUNS #
City
Tacoma
State
WA
Country
United States
Zip Code
98405

  Publications

Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42

Showing the most recent 10 out of 109 publications